Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based ...

Microbion's Phase II trial of pravibismane for diabetic foot ulcer infections showed strong safety and positive efficacy ...

Germany’s Merck KGaA (MRK: DE) was trading 5% lower as Thursday’s trading day neared its end, after the company announced its ...

US ophthalmology specialist Ocular Therapeutix announced that Namrata Saroj has joined the Company on a full-time basis as ...

Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for ...

Swiss clinical-stage biopharma AC Immune saw its shares gain 8% to $3.38 in US trading this morning, after it released ...

While sky high expectations for Eli Lilly’s (NYSE: LLY) tirzepatide have not yet been realized, more positive data add to a ...

Digital therapeutics company GAIA has announced the signing of a licensing agreement for attexis with fellow German firm ...

New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, has closed a $215 million Series ...

Syncona has launched Slingshot Therapeutics with an initial $15 million investment through its Syncona Accelerator initiative ...

Danish allergy immunotherapy specialist ALK Abello today posted financial results for the third quarter of 2024, which ...

USA-based ARTBIO, a radiopharma firm working on alpha radioligand therapies, has entered a global licensing and research partnership with Berlin-based 3B Pharmaceuticals (3BP). The deal grants ARTBIO ...